Walleye Capital
PASG icon

Walleye Capital’s Passage Bio PASG Stock Holding History

Walleye Capital’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-933
Closed -$118K – 2513
2021
Q4 		$118K Buy
+933
New +$152K ﹤0.01% 1631
2021
Q3 		– Sell
-4,240
Closed -$1.12K – 1750
2021
Q2 		$1.12K Buy
+4,240
New +$1.31M 0.04% 409

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Walleye Capital's PASG Position: Q1 2022 in Review

Walleye Capital sold out of Passage Bio (PASG) in Q1 2022, closing a stake of 933 shares — an estimated $118K sold.

Walleye Capital first reported a position in PASG in Q2 2021 and held it in 2 quarters. The position peaked at $118K in Q4 2021. 108 funds tracked by Wall St. Rank hold PASG as of Q1 2022.

  • Walleye Capital reported no remaining Passage Bio position as of Q1 2022 after selling out during the quarter.
  • Walleye Capital sold 933 Passage Bio shares in Q1 2022, an estimated $118K.
  • Walleye Capital first reported a position in Passage Bio in Q2 2021 and held it in 2 quarters.
  • Walleye Capital's Passage Bio position peaked at $118K in Q4 2021.
  • 108 funds tracked by Wall St. Rank held Passage Bio as of Q1 2022.

Based on Walleye Capital's 13F filing for Q1 2022, filed 16 May 2022.